Introduction {#Sec1}
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The WHO recommends nasopharyngeal swab sampling as a reference method to detect SARS-CoV-2 \[[@CR1]\]. However, combined throat/nasal sampling as an alternative has several advantages. This sampling method is easier to execute, is less invasive, can be performed using universal nylon flock swabs which are routinely used in many hospitals, and can provide an alternative in times of nasopharyngeal swab shortage.

A previous comparison between nasopharyngeal and oropharyngeal swab sampling for SARS-CoV-2 in 353 patients showed that the positive rate of nasopharyngeal swabs was higher than that of oropharyngeal swabs (19.0% vs 6.3%) \[[@CR2]\]. Additionally, higher viral loads have been detected in nasal samples compared with throat samples in an analysis of 17 cases \[[@CR3]\] and in a recent study of 146 paired naso- and oropharyngeal samples \[[@CR4]\]. However, a study with 94 patients (37% positive, *n* = 35) showed identical results for nasopharyngeal and middle nasal turbinate sampling, with cycle threshold (Ct) values that did not differ significantly between the two sampling methods \[[@CR5]\]. Also a detailed virological analysis of 9 patients showed no differences in viral loads between naso- and oropharyngeal swabs \[[@CR6]\].

To our knowledge, comparing combined throat/nasal sampling with nasopharyngeal sampling for detection of SARS-CoV-2 has not been described before.

Methods {#Sec2}
=======

Between 21 and 29 April 2020, combined throat/nasal sampling and nasopharyngeal sampling was performed in 107 healthcare workers from a general hospital in the Netherlands. All subjects showed symptoms of COVID-19 such as cough, fever, sore throat, dyspnoea, or loss of smell and taste. Healthcare workers were sampled at least 24 h after the onset of symptoms by a team of nurses who received detailed instructions and training. All healthcare workers were sampled in the early stage of disease, between 24 and 48 h after symptom onset.

Combined throat/nasal swabs were taken by swabbing the rear wall of the oropharynx and the lower nasal cavity using the same swab. For combined throat/nasal sampling, regular swabs with flocked nylon fiber tip in 1 ml liquid Amies medium were used (Eswab Collection system, Copan, Italy, catalog No. 490CE). Subsequently, nasopharyngeal swabs were inserted in one nostril until reaching the back of the nasopharyngeal cavity and rotated before removal. For nasopharyngeal sampling, an ultra-thin applicator swab with flocked nylon fiber tip in 1 ml liquid Amies medium was used (Eswab Collection system, Copan, Italy, catalog No. 483C). Swabs were transported to the microbiology laboratory where PCR testing was performed on the same day.

Detection of SARS-CoV-2 was performed by RT-PCR targeting the E gene. RNA was isolated using the Magnapure MP24 total NA kit (Roche, Almere, the Netherlands) according to the manufacturer's instructions. PCR was performed as described by Corman et al. \[[@CR7]\]. Real-time PCR was performed using the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). A Ct value of 40 was used as the cutoff. No creeping signals or indications for contamination were observed in the PCR.

Results for Ct values are expressed as median with interquartile range (IQR). Summary data were calculated using a Wilcoxon signed ranks test. Statistical analyses were performed with SPSS version 23.0 (Windows, Chicago, USA).

Results {#Sec3}
=======

The median age of the 107 subjects was 34 years (range 19--63 years). A total of 80 healthcare workers (74.8%) tested negative with both sampling methods, and 25 healthcare workers (23.4%) tested positive with both sampling methods. There were two discrepant results with positive PCR in combined throat/nasal swabs and negative PCR in nasopharyngeal swabs (1.9%) (Table [1](#Tab1){ref-type="table"}). The *κ* index for concordance between the 2 sampling methods was high (0.95).Table 1Results of paired SARS-CoV-2 testingNasopharyngeal swab PCRPositiveNegativeTotalCombined throat/nasal swab PCRPositive*n* = 25 (23.4%)*n* = 2 (1.9%)*n* = 27 (25.2%)Negative*n* = 0 (0%)*n* = 80 (74.8%)*n* = 80 (74.8%)Total*n* = 25 (23.4%)*n* = 82 (76.6%)*n* = 107 (100%)

Median Ct value of PCR on nasopharyngeal samples was 19 (range 14--31; IQR 17--20), compared with 21 (range 15--37; IQR 18--29) for combined throat/nasal samples (Fig. [1](#Fig1){ref-type="fig"}). The median cycle threshold (Ct) value of PCR on nasopharyngeal samples was significantly lower than the Ct value of PCR on combined throat/nasal samples (*p* value 0.01). The combined throat/nasal swabs that were positive with negative nasopharyngeal swab PCR had Ct values of 32 and 37.Fig. 1Ct values of paired samples with positive SARS-CoV-2 in both samples

A limitation to our study is the limited number of patients as well as positive samples. However, as we did not observe any positive nasopharyngeal samples with negative throat/nasal swab, double sampling of additional healthcare workers was judged unnecessary. In this study, two different sampling methods were compared in order to determine less invasive and easier to perform sampling techniques. In future studies assessing the utility of different patient samples for the diagnosis of COVID-19, it would be interesting to compare the combined throat/nasal swab with saliva specimens as well.

Conclusion {#Sec4}
==========

Our study shows that combined throat/nasal swabs yield a similar sensitivity to detect SARS-CoV-2 as nasopharyngeal swabs, despite a lower Ct value for the nasopharyngeal samples.
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